The G protein-biased κ-Opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 352, Issue 1, 2015, Pages 98-109

  White, Kate L ^a   Robinson, J Elliott ^a   Zhu, Hu ^a   DiBerto, Jeffrey F ^a   Polepally, Prabhakar R ^b   Zjawiony, Jordan K ^b   Nichols, David E ^a   Malanga, C J ^a   Roth, Bryan L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

22 THIOCYANATOSALVINORIN A; ANALGESIC AGENT; BETA ARRESTIN 2; GUANINE NUCLEOTIDE BINDING PROTEIN; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; SALVINORIN A; UNCLASSIFIED DRUG; 22-THIOCYANATOSALVINORIN A; BETA ARRESTIN; CLERODANE DERIVATIVE; KAPPA OPIATE RECEPTOR; LIGAND; NARCOTIC ANALGESIC AGENT; RETINA S ANTIGEN;

ADVERSE OUTCOME; ANALGESIC ACTIVITY; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; AVERSION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; FEMALE; IN VIVO STUDY; LOCOMOTION; MALE; MOUSE; NONHUMAN; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; CONDITIONING; DRUG EFFECTS; HEK293 CELL LINE; HUMAN; METABOLISM;

ANALGESICS, OPIOID; ANIMALS; ARRESTINS; CONDITIONING (PSYCHOLOGY); DITERPENES, CLERODANE; GTP-BINDING PROTEINS; HEK293 CELLS; HUMANS; LIGANDS; MICE; RECEPTORS, OPIOID, KAPPA; SIGNAL TRANSDUCTION;

EID: 84919770416     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.216820     Document Type: Conference Paper

References (41)

1. Allen JA and Roth BL (2011) Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 51:117-144.
2. Allen JA, Yost JM, Setola V, Chen X, Sassano MF, Chen M, Peterson S, Yadav PN, Huang XP, and Feng B, et al. (2011) Discovery of b-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci USA 108:18488-18493.
3. Ansonoff MA, Zhang J, Czyzyk T, Rothman RB, Stewart J, Xu H, Zjwiony J, Siebert DJ, Yang F, and Roth BL, et al. (2006) Antinociceptive and hypothermic effects of Salvinorin A are abolished in a novel strain of kappa-opioid receptor-1 knockout mice. J Pharmacol Exp Ther 318:641-648.
4. Balter RE and Dykstra LA (2013) Thermal sensitivity as a measure of spontaneous morphine withdrawal in mice. J Pharmacol Toxicol Methods 67:162-168.
5. Besnard J, Ruda GF, Setola V, Abecassis K, Rodriguiz RM, Huang XP, Norval S, Sassano MF, Shin AI, and Webster LA, et al. (2012) Automated design of ligands to polypharmacological profiles. Nature 492:215-220.
6. Bhatnagar A, Willins DL, Gray JA, Woods J, Benovic JL, and Roth BL (2001) The dynamin-dependent, arrestin-independent internalization of 5-hydroxytryptamine 2A (5-HT2A) serotonin receptors reveals differential sorting of arrestins and 5-HT2A receptors during endocytosis. J Biol Chem 276:8269-8277.
7. Bohn LM, Lefkowitz RJ, and Caron MG (2002) Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice. J Neurosci 22:10494-10500.
8. Bruchas MR and Chavkin C (2010) Kinase cascades and ligand-directed signaling at the kappa opioid receptor. Psychopharmacology (Berl) 210:137-147.
9. Bruchas MR, Land BB, Aita M, Xu M, Barot SK, Li S, and Chavkin C (2007) Stress-induced p38 mitogen-activated protein kinase activation mediates kappa-opioiddependent dysphoria. J Neurosci 27:11614-11623.
10. Carlezon WA, Jr and Chartoff EH (2007) Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation. Nat Protoc 2:2987-2995.
11. Cunningham CW, Rothman RB, and Prisinzano TE (2011) Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A. Pharmacol Rev 63: 316-347.
12. DeWire SM, Yamashita DS, Rominger DH, Liu G, Cowan CL, Graczyk TM, Chen XT, Pitis PM, Gotchev D, and Yuan C, et al. (2013) A G protein-biased ligand at the m-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther 344: 708-717.
13. Ebner SR, Roitman MF, Potter DN, Rachlin AB, and Chartoff EH (2010) Depressivelike effects of the kappa opioid receptor agonist salvinorin A are associated with decreased phasic dopamine release in the nucleus accumbens. Psychopharmacology (Berl) 210:241-252.
14. Farrell MS, Pei Y, Wan Y, Yadav PN, Daigle TL, Urban DJ, Lee HM, Sciaky N, Simmons A, and Nonneman RJ, et al. (2013) A Gβs DREADD mouse for selective modulation of cAMP production in striatopallidal neurons. Neuropsychopharmacology 38:854-862.
15. Huang HS, Burns AJ, Nonneman RJ, Baker LK, Riddick NV, Nikolova VD, Riday TT, Yashiro K, Philpot BD, and Moy SS (2013) Behavioral deficits in an Angelman syndrome model: effects of genetic background and age. Behav Brain Res 243: 79-90.
16. Kieffer BL (1999) Opioids: first lessons from knockout mice. Trends Pharmacol Sci 20:19-26.
17. McLaughlin JP, Marton-Popovici M, and Chavkin C (2003) Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci 23:5674-5683.
18. Medvedev IO, Gainetdinov RR, Sotnikova TD, Bohn LM, Caron MG, and Dykstra LA (2005) Characterization of conditioned place preference to cocaine in congenic dopamine transporter knockout female mice. Psychopharmacology (Berl) 180: 408-413.
19. Monasky MM, Taglieri DM, Henze M, Warren CM, Utter MS, Soergel DG, Violin JD, and Solaro RJ (2013) The β-arrestin-biased ligand TRV120023 inhibits angiotensin II-induced cardiac hypertrophy while preserving enhanced myofilament response to calcium. Am J Physiol Heart Circ Physiol 305:H856-H866.
20. Negus SS, Morrissey EM, Rosenberg M, Cheng K, and Rice KC (2010) Effects of kappa opioids in an assay of pain-depressed intracranial self-stimulation in rats. Psychopharmacology (Berl) 210:149-159.
21. Pfeiffer A, Brantl V, Herz A, and Emrich HM (1986) Psychotomimesis mediated by kappa opiate receptors. Science 233:774-776.
22. Potter DN, Damez-Werno D, Carlezon WA, Jr, Cohen BM, and Chartoff EH (2011) Repeated exposure to the k-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity. Biol Psychiatry 70: 744-753.
23. Pradhan AA, Befort K, Nozaki C, Gavériaux-Ruff C, and Kieffer BL (2011) The delta opioid receptor: an evolving target for the treatment of brain disorders. Trends Pharmacol Sci 32:581-590.
24. Prevatt-Smith KM, Lovell KM, Simpson DS, Day VW, Douglas JT, Bosch P, Dersch CM, Rothman RB, Kivell B, and Prisinzano TE (2011) Potential drug abuse therapeutics derived from the hallucinogenic natural product salvinorin A. Medchemcomm 2:1217-1222.
25. Ranganathan M, Schnakenberg A, Skosnik PD, Cohen BM, Pittman B, Sewell RA, and D'Souza DC (2012) Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the k opioid agonist Salvinorin A in humans. Biol Psychiatry 72:871-879.
26. Rives L-M, Rossillo M, Liu-Chen LY, and Javitch JA (2012) 6'-Guanidinonaltrindole (6'-GNTI) is a G protein-biased kappa-opioid receptor agonist that inhibits arrestin recruitment. J Biol Chem 287:27050-27054.
27. Robinson JE, Fish EW, Krouse MC, Thorsell A, Heilig M, and Malanga CJ (2012) Potentiation of brain stimulation reward by morphine: effects of neurokinin-1 receptor antagonism. Psychopharmacology (Berl) 220:215-224.
28. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, and Rothman RB (2002) Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci USA 99:11934-11939.
29. Schattauer SS, Miyatake M, Shankar H, Zietz C, Levin JR, Liu-Chen LY, Gurevich VV, Rieder MJ, and Chavkin C (2012) Ligand directed signaling differences between rodent and human k-opioid receptors. J Biol Chem 287:41595-41607.
30. Shippenberg TS and Herz A (1986) Differential effects of mu and kappa opioid systems on motivational processes. NIDA Res Monogr 75:563-566.
31. Sufka KJ, Loria MJ, Lewellyn K, Zjawiony JK, Ali Z, Abe N, and Khan IA (2014) The effect of Salvia divinorum and Mitragyna speciosa extracts, fraction and major constituents on place aversion and place preference in rats. J Ethnopharmacol 151: 361-364.
32. Tao YM, Li QL, Zhang CF, Xu XJ, Chen J, Ju YW, Chi ZQ, Long YQ, and Liu JG (2008) LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential. Eur J Pharmacol 584:306-311.
33. Tejeda HA, Counotte DS, Oh E, Ramamoorthy S, Schultz-Kuszak KN, Bäckman CM, Chefer V, O'Donnell P, and Shippenberg TS (2013) Prefrontal cortical kappa-opioid receptor modulation of local neurotransmission and conditioned place aversion. Neuropsychopharmacology 38:1770-1779.
34. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, and Sexton PM, et al. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1-13.
35. Waddell AB and Holtzman SG (1999) Modulation of cocaine-induced antinociception by opioid-receptor agonists. Pharmacol Biochem Behav 62:247-253.
36. Wee S and Koob GF (2010) The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology (Berl) 210:121-135.
37. Whalen EJ, Rajagopal S, and Lefkowitz RJ (2011) Therapeutic potential of β-arrestin- and G protein-biased agonists. Trends Mol Med 17:126-139.
38. White KL, Scopton AP, Rives ML, Bikbulatov RV, Polepally PR, Brown PJ, Kenakin T, Javitch JA, Zjawiony JK, and Roth BL (2014) Identification of novel functionally selective k-opioid receptor scaffolds. Mol Pharmacol 85:83-90.
39. Yan F, Bikbulatov RV, Mocanu V, Dicheva N, Parker CE, Wetsel WC, Mosier PD, Westkaemper RB, Allen JA, and Zjawiony JK, et al. (2009) Structure-based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the kappa-opioid receptor. Biochemistry 48:6898-6908.
40. Zhang Y, Butelman ER, Schlussman SD, Ho A, and Kreek MJ (2005) Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacology (Berl) 179:551-558.
41. Zhou L, Lovell KM, Frankowski KJ, Slauson SR, Phillips AM, Streicher JM, Stahl E, Schmid CL, Hodder P, and Madoux F, et al. (2013) Development of functionally selective, small molecule agonists at kappa opioid receptors. J Biol Chem 288: 36703-36716.